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A B S T R A C T
The regioselective Cu(I)-catalyzed 1,3-dipolar cycloaddition of 17α- and 17β-azidoandrost-5-en-3β-ol epimers
(3b and 5b) with diﬀerent terminal alkynes aﬀorded novel 1,4-substituted triazolyl derivatives (8a–k and 9a–k).
For the preparation of 5′-iodo-1′,2′,3′-triazoles (8m–n and 9m–n), an improved method was developed, directly
from steroidal azides and terminal alkynes, in reaction mediated by CuI and ICl as iodinating agents. Acetolysis
and subsequent hydrolysis of 8n and 9n yielded 5′-hydroxy-1′,2′,3′-triazoles 8o and 9o. The inhibitory eﬀect of
8a–o, 9a–o, 3, and 5 on rat testicular C17,20-lyase was investigated by means of an in vitro radioincubation
technique. The results revealed that the C-17 epimers of steroidal triazoles inﬂuence the C17,20-lyase eﬀect.
Inhibitors were found only in the 17α-triazolyl series (8a–o), whereas in the C-17 azide pair the 17β compound
(5b) was more potent.
1. Introduction
Prostate cancer is an age-related disease and a major cause of
cancer-related mortality worldwide. It is androgen dependent in the
majority of cases and can be treated with androgen ablation. Steroidal
precursors are transformed to preandrogens by the 17α-hydroxylase-
C17,20-lyase enzyme (P45017α), which is highly active in both testes and
adrenals [1]. Inhibitors of this enzyme can block androgen synthesis in
its early steps, and may be suitable for pharmacological treatment of
androgen dependent disorders, among them the prostate cancer [2–4].
In the past decades a large number of compounds were developed as
P45017α inhibitors [5,6]. The most promising compounds have been
designed by the ligand-base approach. These are steroidal derivatives
possessing heterocycle on the C-17 position. Heterocycles containing
sp2 hybrid N were demonstrated to be the most eﬀective coordinating
groups to the heme iron of the enzyme active center. The Δ16,17 double
bond can signiﬁcantly increase inhibitory potency [7]. Abiraterone [17-
(3-pyridyl)androsta-5,16-dien-3β-ol] and Galeterone [17-(1H-benzimi-
dazole-1-yl)androsta-5,16-dien-3β-ol] have become the most successful
drug candidates of this group of compounds [8,9].
We previously described the synthesis of series of C-17β
heterocyclic steroids, and investigated their inhibitory activity against
C17,20-lyase in vitro [10–15]. As a continuation of our research program
we set out to prepare 1,4-substituted-1,2,3-triazolyl derivatives in the
androstane series, in which the heterocycle is attached to the steroid C-
17 position.
The Huisgen 1,3-dipolar cycloaddition of organic azides and term-
inal alkynes has been of considerable interest in recent years following
the independent introduction of Cu(I) catalysis in 2002 by the research
groups of Sharpless [16] and Meldal [17]. The catalyst dramatically
improves both the rate and the regioselectivity of the reaction leading
exclusively to 1,4-disubstituted 1,2,3-triazoles.
The synthetic routes involve the introduction of an azide group into
the C-17 position of the sterane framework and the subsequent ring
closure of the steroidal azid with a terminal acetylene in the presence of
a Cu(I) source. The copper(I)-catalyzed azide–alkyne cycloaddition
(CuAAC) is convenient for the regioselective construction of 1,4-dis-
ubstituted triazoles in which the heterocycle is attached directly to the
steroid nucleus through a nitrogen atom.
The position and steric orientation of the azide group are de-
termined by the synthetic method applied. The C-17 azide group is
generally in the α position, because the nucleophilic exchange reaction
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of 17β-tosylate or mesylate by sodium azide takes place with Walden
inversion [18]. Here we decided to synthesize not only the 17α-azides,
but a novel series of 17β-azide epimers, as starting materials for CuAAC
in order to obtain novel 1,4-disubstituted triazolyl androstane deriva-
tives with varied terminal alkynes as reagents.
We set out to obtain answers to the following questions: (1) how the
CuAAC process inﬂuenced by the steric structure of the steroidal azides,
and (2) how the inhibitory activity against C17,20-lyase in the C-17
epimer series diﬀer.
2. Experimental
2.1. General
Melting points (mp) were determined on a Koﬂer block and are
uncorrected. Speciﬁc rotations were measured in CHCl3 (c 1) at 20 ○C
with a POLAMAT-A (Zeiss-Jena) polarimeter and are given in units of
10−1 deg cm2 g−1. Elementary analysis data were determined with a
Perkin-Elmer CHN analyzer model 2400. The reactions were monitored
by TLC on Kieselgel-G (Merck Si 254F) layers (0.25 mm thick); solvent
systems (ss): (A) isopropyl ether, (B) acetone/toluene/hexane
(30:35:35, v/v). The spots were detected by spraying with 5% phos-
phomolybdic acid in 50% aqueous phosphoric acid. The Rf values were
determined for the spots observed by illumination at 254 and 365 nm.
Flash chromatography: silica gel 60, 40–63 μm. All solvents were dis-
tilled prior to use. NMR spectra were recorded on a Bruker DRX 500
instrument at 500 (1H NMR) or 125MHz (13C NMR). Chemical shifts
are reported in ppm (δ scale), and coupling constants (J) in Hertz. For
the determination of multiplicities, the J-MOD pulse sequence was
used.
2.2. 3β-Acetoxy-androst-5-ene-17β-p-toluenesulfonate (2)
3β-Acetoxy-androst-5-en-17β-ol (1, 16.6 g, 50mmol) was dissolved
in pyridine (100m), and a solution of p-toluenesulfonyl chloride
(14.25 g, 75 mmol) in anhydrous pyridine (50ml) was added during
cooling with ice. The reaction mixture was allowed to stand for 24 h
and then poured onto a mixture of ice (500 g) and concentrated H2SO4
(50ml). The crystalline precipitate separating out was ﬁltered oﬀ,
washed thoroughly with water, and recrystallized from a mixture of
acetone and water to give pure 2 (21.55 g, 88%). Mp: 165–166 °C,
Rf = 0.80 (ss A); [α]D20=−70 (c 1 in CHCl3) (Ref. [19] 162–164 °C,
[α]D20=−72, c 1 in ethanol). (Found C, 68.95; H, 7.94. C28H38O5S
requires C, 69.10; H, 7.87%). 1H NMR (δ, ppm, CDCl3): 0.80 and 0.99
(s, 3H, 18-H3, and s, 3H, 19-H3), 2.01 (s, 3H, Ac-CH3), 2.44 (s, 3H, Ts-
CH3), 4.24 (t, 1H, J=8.0 Hz, 17-H), 4.57 (m, 1H, 3-H), 5.33 (d, 1H,
J=4.5 Hz, 6-H), 7.32 (d, 2H, J=8.0 Hz, 3′- and 5′ -H), 7.77 (d, 2H,
J=8.0 Hz, 2′- and 6′-H). 13C NMR (δ, ppm, CDCl3): 11.6 (C-18), 19.3
(C-19), 20.3, 21.4, 21.6, 23.3, 27.6, 31.2, 31.6, 35.9, 36.6(C-3), 36.9,
38.0, 42.8 (C-13), 49.8, 50.2, 73.7 (Ac-CH3), 89.9 (C-17), 121.9 (C-6),
127.8 (C-2′ and C-6′), 129.6 (C-3′ and C-5′), 134.2 (C-4′), 139.8, 144.3
(C-1′), 170.4 (C]O).
2.3. 3β-Acetoxy-androst-5-en-17α-azide (3a)
Compound 2 (9.73 g, 20mmol) was dissolved in N,N-di-
methylformamide (150ml), and NaN3 (5.2 g, 80 mmol) was added. The
mixture was stirred for 48 h at 100 °C, then poured into water (600ml).
The precipitate separating out was ﬁltered oﬀ and washed with water.
The residue obtained was dissolved in CH2Cl2 and chromatographed on
silica gel with CH2Cl2/hexane (1:1, v/v) to give 3a (5.6 g, 78%) as a
white solid. Mp: 153–155 °C, Rf = 0.85 (ss A); [α]D20=−113 (c 1, in
CHCl3). (Found: C, 70.76; H, 8.62; N, 11.93. C21H31N3O2 requires C,
70.55; H, 8.74; N, 11.75%.) 1H NMR (δ, ppm, CDCl3): 0.75 and 1.01 (s,
3H, 18-H3 and s, 3H, 19-H3), 2.02 (s, 3H, Ac-H3), 3.52 (d, 1H,
J= 6.5 Hz, 17-H), 4.60 (m, 1H, 3-H), 5.37 (d, 1H J= 4.5 Hz, 6-H). 13C
NMR (δ, ppm, CDCl3): 17.4 (Ac-CH3, 19.3 (C-18), 20.5, 21.4 (C-19),
24.7, 27.7, 28.6, 32.0, 32.1 (C-8), 32.4, 36.6, 37.0, 38.0, 45.7 (C-13),
49.6 (C-9), 49.8 (C-14), 71.4 (C-17), 73.8 (C-3), 122.3 (C-6), 139.6 (C-
5), 170.5 (C]O).
2.4. 17α-Azido-androst-5-en-3β-ol (3b)
Compound 3a (3.57 g, 10mmol) was dissolved in methanol
(100ml) containing NaOCH3 (108mg, 2mmol), and the solution was
allowed to stand for 24 h. It was then diluted with water and the white
precipitate separating out was separated by ﬁltration and recrystallized
from a mixture of acetone/water to give 3b (3.15 g, 92%). Mp:
132–134 °C, Rf = 0.65 (ss B); [α]D20=−118 (c 1, in CHCl3). (Found:
C, 72.47; H, 9.05; N, 13.51. C19H29N3O requires C, 72.34; H, 9.27; N,
13.32%.) 1H NMR (δ, ppm, CDCl3): 0.77 and 1.01 (s, 3H, 18-H3 and s,
3H, 19-H3), 3.51 (m, 2H, 3-H and –OH), 5.35 (t, 1H, J=2.5 Hz, 6-H).
13C NMR (δ, ppm, CDCl3): 17.4 (C-18), 19.4 (C-19), 20.7, 24.8, 28.7,
31.6, 31.7, 32.1, 32.3, 32.6, 36.6, 37.3, 42.3, 45.8, 49.9, 50.0, 71.6 (C-
17), 71.7 (C-3), 121.4 (C-6), 140.8 (C-5).
2.5. 3β-Acetoxy-androst-5-en-17α-iodide (4)
Compound 1 (5 g, 15mmol), Ph3P (15.78 g, 60.15mmol), and
imidazol (4.10 g, 60.15mmol) were dissolved in toluene (250ml) and
I2 (15.26 g, 60.15mmol) was added in two portions. The reaction
mixture was stirred at 80 °C for 2 h and allowed to cool to room tem-
perature. A saturated aqueous Na2SO3 solution (150ml) was then
added and the resulting mixture was stirred until all solids dissolved.
EtOAC (100ml) was added, and the organic phase was washed with
saturated aqueous NaHCO3 (2×100ml) and brine (100ml), dried over
Na2SO4 and evaporated in vacuo. The residue was subjected to column
chromatography on silica gel in CH2Cl2/hexane (1:3, v/v) to yield 4
(5.27 g, 79%) as a white solid. Mp: 162–164 °C, (Ref. [7] 164–166 °C),
Rf = 0.80 (ss A); [α]D20= –138 (c 1 in CHCl3). (Found: C, 56.93; H,
7.27. C21H31IO2 requires C, 57.02; H, 7.06%). 1H NMR (δ, ppm, CDCl3):
0.84 and 1.02 (s, 3H, 18-H3 and s, 3H, 19-H3), 2.30 (s, 3H, Ac-CH3),
2.79 (m, 1H, 6-H), 4.36 (d, 1H, J=6.5 Hz, 1=H), 4.60 (m, 1H, 3-H),
5.39 (s, 1H, 6-H). 13C NMR (δ, ppm, CDCl3):15.5 (C-18), 19.4 (C-19),
21.4 (Ac-CH3), 21.8, 25.2, 27.7, 31.9, 32.5, 36.6, 36.8, 37.0, 38.1, 40.6,
45.1, 47.7, 49.4 (C-2), 73.8 (C-3), 122.3 (C-6), 139.6 (C-5), 170.4 (Ac-
C]O).
2.6. 3β-Acetoxy-androst-5-en-17β-azide (5a) and 3β-acetoxy-androst-
5,16-diene (6)
Compound 4 (4.42 g, 10mmol) was dissolved in N,N-di-
methylformamide (150ml), and NaN3 (5 g, 75mmol) was added. The
mixture was stirred for 32 h at 60 °C, then poured onto ice (500 g). The
resulting emulsion was extracted with CH2Cl2 (3× 150ml). The
CH2Cl2 phase was washed with water, dried over Na2SO4, evaporated in
vacuo and subjected to chromatographic separation on silica gel in
CH2Cl2/hexane (1:3 v/v) to yield 6 (1.32 g, 42%) as a slowly-crystal-
lizing colourless oil. Mp: 45–46 °C, Rf = 0.85 (ss A); [α]D20= – 92 (c 1
in CHCl3). (Found: C, 80.37; H, 9.46. C21H30O2 requires: C, 80.21; H,
9.62%). 1H NMR (δ ppm, CDCl3): 0.78 and 1.06 (s, 3H, 18-H3 and s, 3H,
19-H3), 2.03 (s, 3H, Ac-CH3), 2.33 (m, 2H, 15-H2), 4.61 (m, 1H, 3-H),
5.39 (d, 1H, J= 5.0 Hz, 6-H), 5.70 (m, 1H, 16-H), 5.84 (dd, 1H,
J= 5.0 Hz, J= 1.0 Hz, 17-H). 13C NMR (δ, ppm CDCl3): 16.8 (Ac-CH3),
19.2 (C-18), 21.4 (C-19), 27.7, 30.4 (C-8), 31.7, 32.1, 35.8, 36.9, 26.9,
38.1, 45.3 (C-13), 50.8 (C-9), 56.1 (C-14), 73.9 (C-3), 122.5 (C-6),
129.3 (C-16), 139.9 (C-5), 143.8 (C-17), 170.5 (C]O). Continued
elution resulted in 5a (1.64 g, 46%) as a white solid. Mp: 143–145 °C,
Rf = 0.75 (ss A); [α]D20=−68 (c 1 in CHCl3). (Found: C, 70.76; H,
8.55; N, 11.94. C21H31N3O2 requires C, 70.55; H, 8.74; N, 11.75%). 1H
NMR (δ, ppm, CDCl3): 0.76 and 1.02 (s, 3H, 18-H3 and s, 3H, 19-H3),
3.32 (t, 1H, J= 9.0 Hz, 17-H), 4.59 (m, 1H, 3-H), 5.36 (d, 1H,
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J= 4.5 Hz, 6-H).
13C NMR (δ, ppm, CDCl3): 12.1 (Ac-CH3), 19.3 (C-18), 20.5, 21.4 (C-
19), 23.6, 26.9, 27.7, 31.5, 31.9 (C-8), 36.6, 37.0, 38.0, 44.2 (C-13),
49.9 (C-9), 52.3 (C-14), 71.2 (C-17), 73.8 (C-3), 122.1 (C-6), 139.7 (C-
5), 170.5 (C]O).
2.7. 17β-Azido-androst-5-en-3β-ol (5b)
Compound 5a (7.15 g, 20 mmol) was dissolved in methanol
(200ml) containing NaOCH3 (270mg, 5mmol), and the solution was
allowed to stand for 24 h. It was then diluted with water, the white
precipitate separating out was ﬁltered oﬀ, recrystallized from a mixture
of acetone/hexane to give 5a (5.45 g, 86%) as a white solid. Mp:
78–80 °C, Rf = 0.60 (ss B); [α]D20=−67 (c 1 in CHCl3). (Found: C,
72.55; H, 9.42; N, 13.65. C19H29N3O requires C, 72.34; H, 9.27; N,
13.32%). 1H NMR (δ, ppm, CDCl3): 0.76 and 1.00 (s, 3H, 18-H3 and s,
3H, 19-H3), 3.31 (t, 1H, J=8.5 Hz, 17-H), 3.50 (m, 1H, 3-H) 5.34 (s,
1H, 6-H). 13C NMR (δ, ppm, CDCl3): 12.1 (C-18), 19.4 (C-19), 20.6,
23.6, 26.9, 31.5, 31.6, 32.0, 37.1, 37.2, 42.1, 42.2, 44.2, 50.0, 52.4,
71.2 (C-17), 71.6 (C-3), 121.1 (C-6), 140.9 (C-5).
2.8. General procedure for the synthesis of triazoles (8a–k and 9a–k)
17α-Azido-androst-5-en-3β-ol (3b) (315.45 mg, 1mmol) or 17β-
azido-androst-5-en (5b) (315.45 mg, 1mmol) was dissolved in CH2Cl2
(20ml), then CuI (19mg, 0.10mmol), Et3N (0.2ml, 2 mmol), and the
appropriate terminal alkyne (7a–k, 2 mmol) were added. The mixture
was stirred under reﬂux for 24 h, then diluted with water (30ml) and
extracted with CH2Cl2 (2×30ml). The combined organic phases were
dried over Na2SO4 and evaporated in vacuo. The crude product was
puriﬁed by ﬂash chromatography using ethyl acetate/CH2Cl2 in dif-
ferent concentrations.
2.8.1. 17α-(4′-Phenyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol (8a)
Compound 3b (315.45 mg, 1mmol) and phenylacetylene (7a,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (1:99 v/v) to yield pure 8a (234mg, 56%) as a white solid. Mp:
234–236 °C; Rf= 0.45 (ss B); [α]D20=−73 (c 1 in CHCl3). (Found: C,
77.52; H, 8.26; N, 9.87. C27H35N3O requires C, 77.66; H, 8.45; N,
10.06%). 1H NMR (δ, ppm, CDCl3): 0.97 and 0.98 (s, 3H, 18-H3 and s,
3H, 19-H3), 3.47 (m, 1H, 3-H), 4.63 (d, 1H, J=7.5 Hz, 17-H), 5.33 (s,
1H, 6-H), 7.32 (t, 1H, J=7.4 Hz, 4″-H), 7.41 (t, 1H, J= 7.4 Hz, 3″- and
5″-H), 7.68 (s, 1H, 5′-H), 7.83 (d, 2H, J=7.4 Hz, 2″-H and 6″-H). 13C
NMR (δ, ppm, CDCl3): 18.4 (C-18), 19.3 (C-19), 20.4, 25.3, 28.6, 31.5,
31.9, 32.2, 32.4, 36.4, 37.1, 42.1, 46.1, 49.4, 50.2, 70.4 (C-17), 71.5 (C-
3), 119.8 (C-5′), 121.1 (C-6), 125.6 and 128.8 (4C, C-2″, C-3″, C-5″ and
C-6″), 128.0 (C-4″), 130.6 (C-1″), 140.7 (C-5), 146.8 (C-4′).
2.8.2. 17α-[4′-(4″-Tolyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-5-en-3β-ol
(8b)
Compound 3b (315.45 mg, 1mmol) and 4-tolylacetylene (7b,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (1:99 v/v) to yield pure 8b (193mg, 45%) as a colorless crys-
talline solid. Mp: 258–261 °C; Rf = 0.45 (ss B); [α]D20=−75 (c 1 in
CHCl3). (Found: C, 78.05; H, 8.42; N, 9.87. C28H37N3O requires C,
77.92; H, 8.64; N, 9.74%). 1H NMR (δ, pm, CDCl3): 0.99 and 1.03 (s,
3H, 18-H3 and s, 3H, 19-H3), 2.40 (s, 3H, 4″eCH3), 3.49 (m, 1H, 3-H),
4.74 (d, 1H, J=6.5 Hz, 17-H), 5.35 (s, 1H, 6-H), 7.27 and 7.84 (d, 2H,
J=7.0 Hz, 3″- and 5″-H, and d, 2H, J=7.0 Hz, 2″-H and 6″-H). 13C
NMR (δ, ppm, CDCl3): 18.4 (C-18), 19.3 (C-19), 20.5, 21.3 (4″eCH3),
25.6, 29.1, 31.5, 31.8, 32.1, 32.5, 36.4, 37.1, 42.1, 46.8, 49,2, 49.7,
69.8 (C-17), 71.5 (C-3), 78.9 (C-4′), 121.5 (C-6), 127.5 and 129.1 (4C,
C-2″, C-3″, C-5″ and C-6″), 127.5 (C-1″), 138.3 (C-4″), 140.5 (C-5),
187.7 (C-5″).
2.8.3. 17α-[4′-(4″-Methoxyphenyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-5-
en-3β-ol (8c)
Compound 3b (315.45 mg, 1mmol) and 4-methoxyphenyl acet-
ylene (7b, 0.22ml) were used for the synthesis as described in Section
2.8. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (5:95 v/v) to yield pure 8c (170mg, 38%) as a white
solid. Mp: 246–248 °C ; Rf = 0.50 (ss B); [α]D20= –74 (c 1 in CHCl3).
(Found: C, 75.34; H, 8.17; N, 9.55. C28H37N3O2 requires C, 75.13; H,
8.33; N, 9.39%). 1H NMR (δ, ppm, CDCl3): 0.97 and 0.99 (s, 3H, 18-H3
and s, 3H, 19-H3), 3.47 (m, 1H, 3-H), 3.83 (s, 3H, 4″eOCH3), 4.61 (d,
1H, J=8.5 Hz, 17-H), 5.34 (d, 1H, J=2.3 Hz, 6-H), 6.95 (d, 2H,
8.2 Hz, 3″-5″eH2), 7.58 (s, 1H, 5′-H), 7.76 (d, 2H, J=8.2 Hz, 2″-H and
6″-H). 13C NMR (δ, ppm, CDCl3): 18.5 (C-18), 19.5 (C-19), 20.5, 25.4,
28.8, 31.7, 32.1, 32.3 (4′-OCH3), 32.6, 36.6, 37.3, 42.3, 46.3, 49.6,
50.3, 55.5, 70.4 (C-17), 114.3 (C-2″ and -6″), 119.0 (C-5′), 121.3 (C-6),
123.6 (C-1″), 127.05 (C-3″ and -5″), 140.8 (C-5), 146.9 (C-4″), 159.6
(C-4′).
2.8.4. 17α-(4′-Cyclopropyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(8d)
Compound 3b (315.45mg, 1mmol) and cyclopropylacetylene (7d,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield pure 8d (360mg, 96%). Mp: 197–200 °C;
Rf = 0.55 (ss B); [α]D20=−70 (c 1 in CHCl3). (Found: C, 75.81; H,
9.08; N, 10.94. C24H35N3O requires C, 75.55; H, 9.25; N, 11.01%). 1H
NMR (δ, ppm, CDCl3): 0.98 and 0.99 (s, 3H, 18-H3 and s, 3H, 19-H3),
3.49 (m, 1H, 3-H), 4.57 (t, 1H, J=8.1, 2.5 Hz, 17-H), 5.33 (d, 1H,
J= 2.3 Hz, 6-H). 13C NMR (δ, ppm, CDCl3): 7.3, 7.4, 7.8, 18.5 (C-18),
19.5 (C-19), 20.6, 22.0, 25.7, 29.1, 29.8, 31.7, 32.0, 32.2, 32.6, 36.6,
37.3, 42.4, 46.9, 49.3, 49.8, 69.7 (C-17), 71.7 (C-3), 121.7 (C-6), 140.6
(C-5).
2.8.5. 17α-(4′-Cyclopentyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(8e)
Compound 3b (315.45 mg, 1mmol) and cyclopentylacetylene (7e,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield pure 8e (300mg, 45%). Mp: 108–110 °C;
Rf = 0.53 (ss B); [α]D20= –68 (c 1 in CHCl3). (Found: C, 76.38, H, 9.47;
N, 10.03. C26H39N3O requires C, 76.24; H, 9.60; N, 10.26%). 1H NMR
(δ, ppm, CDCl3): 0.93 and 0.98 (s, 3H, 18-H3 and s, 3H, 19-H3), 3.15 (t,
1H, J= 8.2 Hz, 1′-H), 3.48 (m, 1H, 3-H), 4.52 (t, 1H, J=8.6 Hz, 17-H),
5.34–5.33 (m, 1H, 6-H),7.13 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3):
18.5 (C-18), 19.5 (C-19), 20.6, 22.8, 25.3, 25.5, 28.8, 31.7, 32.1, 32.4,
32.5, 33.4, 33.4, 36.6, 36.9, 37.3, 42.3, 46.2, 49.6, 50.3, 70.1 (C-17),
71.7 (C-3), 120.0 (C-5′), 121.3 (C-6), 140.9 (C-5), 151.9 (C-4′).
2.8.6. 17α-(4′-Cyclohexyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(8f)
Compound 3b (315.45 mg, 1mmol) and cyclohexylacetylene (7f,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield pure 8f (240mg, 71%) as white crystalline
product. Mp: 127–129 °C; Rf = 0.50 (ss B); [α]D20= –65 (c 1 in CHCl3).
(Found C, 76.73; H, 9.55; N, 10.06. C27H41N3O requires C, 76.55; H,
9.76; N, 9.92%). 1H NMR (δ, ppm, CDCl3): 0.92 and 0.98 (s, 3H, 18-H3
and s, 3H, 19-H3), 2.73 (m, 1H, 1″-H), 3.48 (m, 1H, 3-H), 4.52 (d, 1H,
J=8.5 Hz, 17-H), 5.33 (t, 1H, J= 2.3 Hz, 5-H), 7.12 (s, 1H, 5′-H). 13C
NMR (δ, ppm, CDCl3): 18.5 (C-18), 19.5 (C-19), 20.5, 25.5, 26.2, 26.2,
26.3, 28.7, 31.7, 32.1, 32.3, 32.5, 33.2, 33.2, 35.4, 36.6, 37.3, 42.3,
46.2, 49.6, 50.3, 70.1 (C-17), 71.7 (C-3), 119.6 (C-5′), 121.3 (C-6),
140.9 (C-5), 152.9 (C-4′).
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2.8.7. 17α-[4′-(2″-Pyridyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-5-en-3β-ol
(8g)
Compound 3b (315.45 mg, 1mmol) and 2-ethynylpyridine (7g,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield pure 8 g (270mg, 64%) as a white solid.
Mp: 211–213 °C; Rf = 0.30 (ss B); [α]D20= –88 (c 1 in CHCl3). (Found
C, 74.48; H, 8.35; N, 13.12. C26H34N4O requires C, 74.61; H, 8.19; N,
13.39%). 1H NMR (δ, ppm, CDCl3): 0.97 (s, 6H, 18–19-H6), 3.46 (m,
1H, 3-H), 4.71–4.70 (m, 1H, 17-H), 5.32–5-31 (m, 1H, 6-H), 7.22–7.20
(m, 1H, 5″-H), 7.76 (m, 1H, 4″-H), 8.09 (s, 1H, 5′-H), 8.19 (d, 1H,
J=7.9 Hz, 3″-H), 8.56–8.55 (m, 1H, 6″-H). 13C NMR (δ, ppm, CDCl3):
18.0 (C-18), 19.0 (C-19), 20.0, 24.9, 28.4, 31.1, 31.49, 31.8, 32.1, 36.1,
36.7, 41.8, 45.7, 49.0, 49.9, 70.0 (C-17), 71.1 (C-3), 120.0, 120.8 (C-6),
121.3 (C-1′), 122.4, 136.6, 140.3 (C-5), 147.1 (C-1″), 148.9 (C-3″),
150.1 (C-4′).
2.8.8. 17α-(4′-Phenoxymethyl-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(8h)
Compound 3b (315.45mg, 1mmol) and phenyl propargyl ether
(7h, 0.22ml) were used for the synthesis as described in Section 2.8.
The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (15:85 v/v) to yield pure 8 h (332mg, 76%) as white
crystals. Mp: 173–175 °C; Rf = 0.50 (ss B); [α]D20= –54 (c 1 in CHCl3).
(Found C, 75.05; H, 8.51; N, 9.952. N28H37N3O2 requires C, 75.13; H,
8.33; N, 9.39%). 1H NMR (δ, ppm, CDCl3): 0.91 and 0.95 (s, 3H, 18-H3
and s, 3H, 19-H3), 3.46 (m, 1H, 3-H), 4.55 (d, 1H, 17-H), 5.18 (s, 2H, 4′-
CH2-O-), 5.31 (t, 1H, 6-H), 6.93 (m, 3H, 2″-H, 4″-H and 6″-H), 7.24 (t,
2H, 3″-, 5″-H), 7.50 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3): 18.3 (C-
18), 19.3 (C-19), 20.4, 25.3, 28.6, 31.5, 32.2, 32.4, 36.4, 37.1, 42.2,
46.1, 49.3, 50.0, 62.2, 70.3 (C-17), 71.5 (C-3), 114.9 (C-2″ and -6″),
121.2 (C-6 and C-4″), 122.8 (C-5′), 129.4 (C-3″ and -5″), 140.7 (C-5),
143.4 (C-4′), 158.1 (C-1″).
2.8.9. 17α-(4′-Benzoyloxymethyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-
3β-ol (8i)
Compound 3b (315.45 mg, 1mmol) and propargyl benzoate (7i,
0.20 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield pure 8i (385mg, 81%) as a white solid. Mp:
222–223 °C; Rf = 0.45 (ss B); [α]D20=−56 (c 1 in CHCl3). (Found C,
73.48; H, 7.66; N, 8.68. C29H37N3O3 requires C, 73.23; H, 7.84; N,
8.83%). 1H NMR (δ, ppm, DMSO): 0.90 and 0.92 (s, 3H, 18-H3 and s,
3H, 19-H3), 3.21 (m, 1H, 3-H), 4.61 (d, 1H, J=4.5 Hz, eOH), 4.62 (d,
1H, J=7.5 Hz, 17-H), 5.26 (s, 1H, 6-H), 5.39 (s, 2H, eCH2eOe), 7.51
(t, 2H, J=7.5 Hz, 3″- and 5″ -H), 7.66 (t, 1H, J=7.5 Hz, 4″-H), 7.95
(d, 2H, J=7.5 Hz, 2″-H and 6″-H), 8.24 (s, 1H, 5′-H). 13C NMR (δ, ppm,
DMSO): 17.7 (C-18), 19.1 (C-19), 19.9, 24.9, 28.0, 31.3, 31.5, 31.6,
31.9, 36.0, 36.8, 42.1, 45.4, 49.3, 49.6, 58.0 (4′-CH2-), 69.0 (C-17),
69.9 (C-3), 120.2 (C-6), 125.2 (C-5′), 128.7 (C-2″ and -6″), 129.1 (C-3″
and -5″), 129.3 (C-1″), 133.4 (C-4″), 141.1 (C-4′), 141.1 (C-5), 165.4
(C]O).
2.8.10. 17α-[4′-(4″-Toluoyloxymethyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-
5-en-3β-ol (8j)
Compound 3b (315.45 mg, 1mmol) and propargyl 4-methyl-
benzoate (7j, 0.20 ml) were used for the synthesis as described in
Section 2.8. The crude product was chromatographed on silica gel with
ethyl acetate/CH2Cl2 (10:90 v/v) to yield pure 8j (430mg, 88%) as a
white crystalline solid. Mp: 250–252 °C; Rf = 0.48 (ss B); [α]D20= –55
(c 1 in CHCl3). (Found C, 73.72; H, 7.95; N, 8.44. C30H39N3O3 requires
C, 73.59; H, 8.03; N, 8.58%). 1H NMR (δ, ppm, DMSO): 0.90 and 0.92
(s, 3H, 18-H3 and s, 3H, 19-H3), 2.37 (s, 3H, 4″eH3), 4.60 (d, 1H,
J= 4.5 Hz, 3-H), 4.69 (d, 1H, J= 8.0 Hz, 17-H), 5.27 (d, 1H,
J= 3.0 Hz, 6-H), 5.36 (s, 2H, 4′-H2), 7.32 (d, 2H, J= 8.0 Hz, 3″- and
5″-H), 7.84 (d, 2H, J= 8.0 Hz, 2″- and 6″-H), 8.22 (s, 1H, 5′-H). 13C
NMR (δ, ppm, DMSO): 17.7 (C-18), 19.1 (C-19), 19.9, 24.9, 28.0, 31.3,
31.5, 31.6, 31.9, 36.0, 36.8, 42.1, 45.4, 49.3, 49.6, 58.0, 69.0, (C-17),
69.9 (C-3), 120.1 (C-6), 125.2 (C-5′), 128.7 and 129.1 (C-4, C-2″, C-3″,
C-5″ and C-6″), 133.5 (C-1″), 141.0 (C-5), 141.1 (C-4′), 165.4 (C]O).
2.8.11. 17α-[4′-(4″-Nitrobenzoyloxymethyl)-1′H-1′,2′,3′-triazol-1′-yl]
androst-5-en-3β-ol (8k)
Compound 3b (315.45 mg, 1mmol) and propargyl 4-nitrobenzoate
(7k, 411mg) were used for the synthesis as described in Section 2.8.
The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (10:90 v/v) to yield pure 8 k (360mg, 62%) as pale
yellow crystals. Mp: 201–202 °C; Rf = 0.45 (ss B); [α]D20= –63 (c 1 in
CHCl3). (Found C, 67.02; H, 6.75; N, 10.85. C29H36N4O5 requires C,
66.90; H, 6.97; N, 10.76%). 1H NMR (δ, ppm, CDCl3): 0.95 and 0.97 (s,
3H, 18-H3 and s, 3H, 19-H3), 3.47 (m, 1H, 3-H), 4.59 (d, 1H, J=7.5 Hz,
6-H), 5.49 (s, 2H, 4′-H2), 7.61 (s, 1H, 5′-H), 8.20 (d, 2H, J=9.0 Hz, 3″-
and 5″-H), 8.26 (d, 2H, J=9.0 Hz, 2″- and 6″-H). 13C NMR (δ, ppm,
CDCl3): 18.4 (C-18), 19.3 (C-19), 20.3, 25.3, 28.7, 31.5, 31.9, 32.1 (C-
8), 32.4, 36.4, 37.1, 42.1, 46.1 (C-13), 49.4 (C-9), 50.1 (C-14), 58.9 (4′-
CH2-), 70.4, (C-17), 71.5 (C-3), 121.1 (C-6), 123.5 (C-2″ and C-6″),
124.4 (C-5′), 130.9 (C-3″ and C-5″), 135.1 (C-1′), 140.7 (C-5), 141.2 (C-
4′), 150.6 (C-4″), 164.6 (C]O).
2.8.12. 17α-(4′-Hydroxymethyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-
3β-ol (8l)
Compound 8k (520mg, 1mmol) was dissolved in methanol (10ml)
containing NaOCH3 (27mg, 0.5mmol), and the solution was allowed to
stand for 24 h. It was then diluted with water, and the white precipitate
separating out was ﬁltered oﬀ, dried and recrystallized from a mixture
of ethyl acetate/hexane to aﬀord 8l (350mg, 94%) as a white solid. Mp:
217–219 °C; Rf=0.20 (ss B); [α]D20= – 38 (c 1 in ethanol). (Found C,
71.25; H, 9.03; N, 11.16. C22H33N3O2 requires C, 71.12; H, 8.95; N,
11.31%). 1H NMR (δ, ppm, DMSO): 0.89 and 0.93 (s, 3H, 18-H3 and s,
3H, 19-H3), 4.49 (d, 2H, J=5.0 Hz, 4′-CH2-), 5.14 (d, 1H, J= 5.0 Hz,
17-H), 5.27 (s, 1H, 6-H), 7.92 (s, 1H, 5′-H). 13C NMR (δ, ppm, DMSO):
17.8 (C-18), 19.1 (C-19), 19.9, 24.9, 28.0, 31.3, 31.5, 31.6 (C-8), 31.9,
36.0, 36.8, 42.1, 45.3, 49.3 (C-9), 49.6 (C-14), 55.0 (4′-CH2-), 68.8 (C-
17), 69.9 (C-3), 120.2 (C-6), 123.0 (C-5′), 141.1 (C-4′), 147.1 (C-5).
2.9. General procedure for the synthesis of 5′-iodotriazoles (8m-k and
9m–k)
Compound 3b or 5b (315.45 mg, 1mmol) was dissolved in CH2Cl2
(20ml), then Et3N (0.2ml, 2 mmol), substituted acetylene derivative
(7m–k, 2 mmol), ICl (1.5 mmol) and, ﬁnally, CuI (190mg, 10mol) were
added. The heterogeneous reaction mixture was stirred under N2 for
24 h, then diluted with 1% N2S2O3 solution (30ml), and extracted with
CH2Cl2 (2×30ml). The combined organic phases were dried over
Na2SO4 and evaporated in vacuo. The crude product was puriﬁed by
ﬂash chromatography using ethyl acetate/CH2Cl2 (5:95 v/v) to obtain
the steroidal 5′-iodotriazoles (8m–n and 9m–n).
2.9.1. 17α-[4′-(4″-Nitrobenzoyloxymethyl)-5′-iodo-1′H-1′,2′,3′-triazol-
1′-yl]androst-5-en-3β-ol (8m)
Compound 3b (315.45 mg, 1mmol) and propargyl 4-nitrobenzoate
(7k, 204mg) were used for the synthesis as described in Section 2.9.
The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (5:95 v/v) to yield a pale yellow crystalline material
(320mg, 49%). Mp: 278–281 °C; Rf = 0.60 (ss B); [α]D20=+81 (c 1 in
CHCl3). (Found C, 54.02; H, 5.37; N, 8.55. C29H35IN4O5 requires C,
53.87; H, 5.46; N, 8.67%). 1H NMR (δ, ppm, CDCl3): 0.99 and 1.02 (s,
3H, 18-H3 and s, 3H, 19-H3), 3.50 (m, 1H, 3-H), 4.64 (dd, 1H,
J= 9.0 Hz, J= 4.5 Hz, 17-H), 5.35 (d, 1H, J= 6.5 Hz, 6-H), 5.47 (d,
2H, J= 5.5 Hz, 4′-H2), 8.22 (d, 2H, J= 11.0 Hz, 3″-H and 5″-H), 8.27
(d, 2H, J= 11.0 Hz, 2″-H and 6″-H). 13C NMR (δ, ppm, CDCl3): 18.4 (C-
18), 19.4 (C-19), 20.5, 25.6, 29.1, 31.5, 31.8, 32.1, 32.5, 36.4, 37.1,
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42.2 (C-13), 46.9, 49.2 (C-9), 49.7 (C-14), 59.1 (4′-CH2-), 70.3 (C-17),
71.6 (C-3), 121.4 (C-5′), 121.5 (C-6), 123.5 (C-2″ and C-6″), 11.0 (C-3″
and C-5″), 135.1 (C-1′), 140.5 (C-5), 145.1 (C-4′), 150.6 (C-4″), 164.3
(C]O).
2.9.2. 17α-(4′-Cyclopropyl-5′-iodo-1′H-1′,2′,3′-triazol-1′-yl)androst-5-
en-3β-ol (8n)
Compound 3b (315.45 mg, 1mmol) and cyclopropylacetylene (7d,
0.22 ml) were used for the synthesis as described in Section 2.9. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield 8n (285mg, 57%) as white crystals. Mp:
176–179 °C; Rf = 0.55 (ss B); [α]D20=+43 (c 1 in CHCl3). (Found C,
56.63; H, 6.89; N, 8.42. C24H34IN3O requires C, 56.80; H, 6.78; N,
8.28%). 1H NMR (δ, ppm, CDCl3): 0.92 and 0.98 (s, 3H, 18-H3 and s,
3H, 19-H3), 3.50 (m, 1H, 3-H), 4.51 (d, 1H, J=5.5 Hz, 17-H), 5.33 (d,
1H, J=4.5 Hz, 6-H). 13C NMR (δ, ppm, CDCl3): 7.2 and 7.7 (C-2″ and
C-3″), 18.4 (C-18), 19.3 (C-19), 20.4, 25.3, 28.6, 31.5, 31.9, 32.1, 32.3,
36,5, 37.1, 42.2, 46.0 (C-13), 49.4 (C-14), 50.1, 70.0 (C-17), 71.5 (C-3),
121.5 (C-6), 140.4 (C-5), 149.2 (C-4′), 180.5 (C-5′).
2.10. General procedure for the synthesis of 5′-hydroxytriazoles (8o, 9o)
Compound 8m or 9m (127mg, 0.25mmol) was dissolved in Ac2O
(3 ml) containing KOAc (196mg, 2mmol), and the mixture was treated
at reﬂux temperature for 4 h. The progress of the reaction was mon-
itored by TLC. After completion of the transformation, the reaction
mixture was diluted with water, then extracted with CH2Cl2
(2× 30ml). The CH2Cl2 solution was washed with NaHCO3 solution
and then with water, dried and evaporated in vacuo. The residual yellow
oil was dissolved in methanol (15ml) containing KOH (56mg, 1mmol)
and the solution was treated at reﬂux temperature for 2 h. The pre-
cipitate separating out was ﬁltered oﬀ and recrystallized from a mixture
of acetone/water.
2.10.1. 17α-(4′-Cyclopropyl-5′-hydroxy-1′H-1′,2′,3′-triazol-1′-yl)
androst-5-en-3β-ol (8o) Compound 8n (127 mg, 0.25 mmol) were used for
the synthesis described in Section 2.10
8o (68mg, 69%). Mp: 193–195 °C; Rf = 0.15 (ss B); [α]D20= –40 (c
1 in ethanol). (Found C, 72.68; H, 8.45; N, 10.72. C24H35N3O2 requires
C, 72.51; H, 8.87; N, 10.57%). 1H NMR (δ, ppm, DMSO): 0.87 and 0.92
(s, 3H, 18-H3 and s, 3H, 19-H3), 2.33 (m, 1H, 3-H), 4.04 (d, 1H,
J=8.5 Hz, 17-H), 4.28 (d, 1H, J=8.0 Hz, 6-H), 5.27 (s, 1H, 5′-OH).
13C NMR (δ, ppm, DMSO): 5.0 (C-18), 6.2, 6.6, 10.0 (C-19), 17.9, 19.1
(C-8), 19.9, 25.1, 27.1, 31.3, 31.6 (C-9), 36.0, 36.8, 42.1 (C-13), 45.3
(C-5′), 49.3 (C-14), 49.4 (C-1″), 50.8, 61.6, 63.6 (C-17), 69.9 (C-3),
120.2 (C-6), 141.1 (C-4′), 172.5 (C-5).
2.10.2. 17β-(4′-Phenyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol (9a)
Compound 5b (315.45 mg, 1mmol) and phenylacetylene (7a,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (1:99 v/v) to yield pure 9a (283mg, 68%) as a white crystalline
product. Mp: 280–283 °C; Rf = 0.40 (ss B); [α]D20= –40 (c 1 in CHCl3).
(Found: C, 77.48; H, 8.31; N, 10.27. C27H35N3O requires C, 77.66; H,
8.45; N, 10.6%). 1H NMR (δ, ppm, DMSO): 0.95 and 1.24 (s, 3H, 18-H3
and 19-H3), 4.52 (t, 1H, J= 9.5 Hz, 17-H), 4.61 (d, 1H, J= 4.0 Hz, 3-
H), 5.31 (dd, 1H, J= 4.0 Hz, J= 1.5 Hz, 6-H), 7.32 (t, 1H, J= 7.5 Hz,
4″-H), 7.44 (t, 2H, J= 7.5 Hz, 3″-H and 5″-H). 13C NMR (δ, ppm,
DMSO): 12.5 (C-18), 19.6 (C-19), 21.0, 23.8, 26.1, 31.4, 31.7, 32.4,
36.9, 37.2, 37.6, 42.1 (C-13), 44.7, 50.4, (C-9), 53.5 (C-14), 71.2 (C-
17), 71.4 (C-3), 120.0 (C-6), 121.2 (C-5′), 126.0 (C-2″ and C-6″), 128.6,
129.2 (C-3″ and C-5″), 130.6, 141.4, (C-5), 147.4 (C-4′).
2.10.3. 17β-[4′(4″-Tolyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-5-en-3β-ol
(9b)
Compound 5b (315.45 mg, 1mmol) and 4-tolylacetylene (7b,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (99:1 v/v) to yield pure 9b (210mg, 77%) as a white crystalline
material. Mp: 293–295 °C; Rf = 0.45 (ss B); [α]D20= –42 (c 1 in
CHCl3). (Found C, 77.78; H, 8.83; N, 9.54. C28H37N3O requires C,
77.92; H, 8.64, N, 9.79%). 1H NMR (δ, ppm, DMSO): 0.51 and 0.94 (s,
3H, 18-H3 and s, 3H, 19-H3), 4.49 (s, 1H, 17-H), 4.53 (d, 1H,
J= 2.0 Hz, 3-H), 5.30 (d, 2H, J= 2.0 Hz, 6-H2), 7.24 (d, 2H,
J= 1.5 Hz, 3″- H and 5″- H), 7.75 (d, 2H, J= 1.5 Hz, 2″- H and 6″- H),
8.59 (s, 1H, 5′- H).
2.10.4. 17β-[4′(4″-Methoxyphenyl)-1′H-1′,2′,3′-triazol-1′-yl]androst-5-
en-3β-ol (9c)
Compound 5b (315.45 mg, 1mmol) and 4-methoxyphenyl acet-
ylene (7c, 0.22 ml)) were used for the synthesis as described in Section
2.8. The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (5:95 v/v) to yield pure 9c (143mg, 67%) as a white
solid. Mp: 260–262 °C; Rf = 0.40 (ss B); [α]D20= –30 (c 1 in CHCl3).
(Found C, 75.27; H, 8.22; N, 9.46. C28H37N3O2 requires C, 75.13; H,
8.33; N, 9.39%). 1H NMR (δ, ppm, CDCl3): 0.62 and 1.01 (s, 3H, 18-H3
and s, 3H, 19-H3) 3.53 (m, 1H, 3-H), 3.84 (eOCH3), 4.43 (t, 1H,
J=9.5 Hz, 17-H), 5.38 (s, 1H, 6-H), 6.95 (d, 2H, J=8.5 Hz, 2″- and 6″-
H), 7.67 (s, 1H, 5′-H), 7.76 (d, 2H, J=8.5 Hz, 3″-H and 5″-H). 13C NMR
(δ, ppm, CDCl3): 12.0 (C-18), 19.4 (C-19), 20.7, 23.5, 25.9, 31.5, 31.6,
32.0, 36.9, 37.2, 42.2, 44.3, 50.1, 53.2, 55.3, 63.3, 65.2, 70.2, 71.6 (C-
3), 114.2 (2C, C-2″ and C-6″), 118.3 (C-5′) 121.0 (C-6), 126.9 (2C, C-3″
and C-5″), 140.9 (C-5), 149.0, 159.6.
2.10.5. 17β-(4′-Cyclopropyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(9d)
Compound 5b (315.45mg, 1mmol) and cyclopropylacetylene (7d,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (1:99 v/v) to yield pure 9d (170mg, 45%). Mp: 242–244° C;
Rf = 0.48 (ss B); [α]D20=−36 (c 1 in CHCl3). (Found C, 75.62; H,
9.03; N, 11.25. C24H35N3O requires C, 75.55; H, 9.25; N, 11.01%). 1H
NMR (δ, ppm, CDCl3): 0.55 and 1.00 (s, 3H, 18-H3 and s, 3H, 19-H3),
3.52 (m, 1H, 3-H), 4.32 (t, 1H, J=9.5 Hz, 17-H), 5.35 (d, 1H,
J=5.0 Hz, 6-H), 7.23 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3): 6.6 (C-
18), 7.8 (C-2″ and C-3″), 11.4 (C-19), 19.4 (C-8), 20.6, 23.4, 25.8, 29.7,
31.5, 31.6, 32.0 (C-9), 36.3, 36.9, 37.2, 42.2, 44.2 (C-13), 50.0 (C-14),
53.1 (C-1″), 70.5 (C-17), 71.6 (C-3), 119.3 (C-6), 121.0 (C-4′), 141.0 (C-
5), 149.2 (C-5′).
2.10.6. 17β-(4′-Cyclopentyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(9e)
Compound 5b (315.45 mg, 1mmol) and cyclopentylacetylene (7e,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield 9e (290mg, 71%) as a white crystalline
product. Mp: 275–277 °C; Rf = 0.45 (ss B); [α]D20=−48 (c 1 in
CHCl3). (Found C, 76.38; H, 9.83; N, 10.12. C26H39N3O requires C,
76.24; H, 9.60; N, 10.26%). 1H NMR (δ, ppm, CDCl3): 0.53 and 0.98 (s,
3H, 18-H3 and s, 3H, 19-H3), 3.50 (m, 1H, 3-H), 4.33 (t, 1H, J=9.5 Hz,
17-H), 5.34 (s, 1H, 6-H), 7.21 (d, 2H, J=8.0 Hz, 2″- and 6″-H), 7.67 (s,
1H, 5′-H), 7.92 (d, 2H, J=8.0 Hz, 3″- and 5″-H). 13C NMR (δ, ppm,
CDCl3): 11.9 (C-18), 19.3 (C-19), 20.6, 23.4, 25.1, 25.8, 31.4 (C-13),
32.0, 33.1, 33.2, 36.5, 36.7, 36.8, 37.2, 42.0, 44.1, 50.0, 53.1, 70.4 (C-
17), 71.4 (C-3), 119.1 (C-5′), 121.0 (C-6), 141.0 (C-5), 151.8 (C-4′).
2.10.7. 17β-(4′-Cyclohexyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-3β-ol
(9f)
Compound 5b (315mg, 1mmol) and cyclohexyacetylene (7f,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield 9f (250mg, 59%) as a white solid. Mp:
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296–297 °C; Rf = 0.40 (ss B); [α]D20=−49 (c 1 in CHCl3). (Found C,
76.73; H, 9.55; N, 9.76. C27H41N3O requires C, 76.55; H, 9.76; N,
9.92%). 1H NMR (δ, ppm, CDCl3): 0.55 (s, 3H, 18-H3), 1.01 (s, 3H, 19-
H3), 1.84 (m, 8H, 2″-, 3″-, 5″- and 6″-H2), 3.40 (m, 1H, 3-H), 4.45 (t,
1H, J=9.5 Hz, 17-H), 5.34 (dd, 1H, J=3.5 Hz, J=2.5 Hz, 6-H), 7.71
(s, 1H, 4′-H).
2.10.8. 17β-[4′(2″-Pyridyl)-1′H-1′,2′,3′-triazol-1′-yl)]androst-5-en-3β-ol
(9g)
Compound 5b (315mg, 1mmol) and 2-ethynylpiridine (7g,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield 9g (330mg, 79%) as a white crystalline
material. Mp: 254–256 °C; Rf = 0.35 (ss B); [α]D20= –34 (c 1 in
CHCl3). (Found C, 74.38; H, 8.25; N, 13.55. C26H34N4O requires C,
74.61; H, 8.19; N, 13.39%). 1H NMR (δ, ppm, CDCl3): 1.00 and 1.24 (s,
3H, 18-H3 and s, 3H 19-H3), 3.53 (m, 1H, 3-H), 4.46 (t, 1H, J=9.5 Hz,
17-H), 5.36 (s, 1H, 6-H), 7.21 (t, 1H, J=6.1 Hz, 5″-H), 7.77 (m, 1H, 4″-
H), 8.18 (s, 1H, 5′-H), 8.20 (s, 1H, 3″-H), 8.57 (d, 1H J=4.1 Hz, 5″-H).
13C NMR (δ, ppm, CDCl3): 12.0 (C-18), 19.4 (C-19), 20.6, 23.5, 25.9,
29.7, 31.5, 31.6, 32.0, 36.9, 37.2, 42.2, 44.3 (C-13), 50.0, 53.2, 70.7 (C-
17), 71.6 (C-3), 120.2, 121.0 (C-6), 121.4 (C-5′), 122.7, 131.9, 141.0
(C-5), 147.4 (C-1″), 149.3 (C-3″), 150.5 (C-4′).
2.10.9. 17β-(4′-Phenoxymethyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-en-
3β-ol (9h)
Compound 5b (315mg, 1mmol) and phenyl propargyl ether (7h,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield 9h (356mg, 79%) as white crystals. Mp:
198–201 °C; Rf = 0.48 (ss B); [α]D20= – 46 (c 1 in CHCl3). (Found C,
75.36; H, 8.22; N, 9.51. C28H37N3O2 requires C, 75.13; H, 8.33; N,
9.39%). 1H NMR (δ, ppm, CDCl3): 0.56 and 1.00 (s, 1H, 18-H3 and s,
1H, 19-H3, and q, J=11.0 Hz, 1H), 3.52 (m, 1H, 3-H), 4.39 (t, 1H,
J=9.5 Hz, 17-H), 5.21 (s, 1H, 4′-CH2-), 3.53 (d, 1H, J=2.5 Hz, 6-H),
5.45 (s, 1H, 4′-CH2-) 6.97 (overlapping multiplets, 3H, 3″-,4″- and 5″-
H), 7.29 (t 2H, J=8.3 Hz, 2″-H and 6″-H), 7.60 (s, 1H, 5′-H). 13C (δ,
ppm, CDCl3): 12.0 (C-18), 19.4 (C-19), 20.6, 23.5, 25.9, 31.4, 31.5,
32.0, 36.5, 36.8, 37.2, 42.2, 44.2, 50.0, 53.1, 62.2 (4′-CH2-), 70.6, 71.6
(C-3), 114.8 (2C, C-2″ and C-6″) 121.0 (C-6), 121.2, 122.1, 1129.5 (2C,
C-3″ and C-5″), 141.0 (C-5), 143.4, 158.2.
2.10.10. 17β-(4′-Benzoyloxymethyl-1′H-1′,2′,3′-triazol-1′-yl)androst-5-
en-3β-ol (9i)
Compound 5b (315mg, 1mmol) and propargyl benzoate (7i,
0.22 ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield 9i (230mg, 48%) as a white solid. Mp
203–206 °C; Rf = 0.40 (ss B); [α]D20= –50 (c 1 in CHCl3). (Found C,
73.42; H, 8.02; N, 8.67. C29H37N3O3 requires C, 73.23; H, 7.84; N,
8.83%). 1H NMR (δ, ppm, CDCl3) 0.55 and 0.99 (s, 3H, 18-H3 and s, 3H,
19-H3), 3.52 (m, 1H, 3-H), 4.40 (t, 1H, J=9.5 Hz, 17-H), 5.35 (s, 1H, 6-
H), 5.47 (s, 2H, eCH2-O-), 7.42 (t, 2H, J=7.5 Hz, 3″-H and 5″-H), 7.55
(t, 1H, J=7.5 Hz, 4″-H), 7.69 (s, 1H, 5′-H), 8.03 (d, 2H, J=7.5 Hz, 2″-
H and 6″-H). 13C NMR (δ, ppm, CDCl3) 12.0 (C-18), 19.4 (C-19), 20.6,
23.4, 25.9, 29.7, 31.4, 31.5, 32.0, 36.5, 36.8, 37.2, 42.1, 44.2, 50.0,
53.1, 58.2, 70.6 (C-17), 71.5 (C-3), 121.0 (C-6), 123.5 (C-5′), 128.3 and
129.7 (4C, C-2″, C-3″, C-5″ and C-6″), 133.1 (C-4″), 140.9, 142.0, 166.5
(C]O).
2.10.11. 17β-[4′-(4″-Toluoyloxymethyl)-1′H-1′,2′,3′-triazol-1′-yl]
androst-5-en-3β-ol (9j)
Compound 5b (315mg, 1mmol) and propargyl 4-methylbenzoate
(7j, 0.22ml) were used for the synthesis as described in Section 2.8. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield 9j (250mg, 51%) as a white solid. Mp:
212–215 °C; Rf = 0.45 (ss B); [α]D20= – 48 (c 1 in CHCl3). (Found C,
73.70; H, 9.87, N, 8.75. C30H39N3O3 requires C, 73.59, H, 8.03; N,
8.58%). 1H NMR (δ, ppm, CDCl3): 0.55 and 0.99 (s, 3H, 18-H3 and s,
3H, 19-H3), 2.39 (s, 3H, 4″eH3), 2.51 (m, 1H), 3.53 (m, 1H, 3-H), 4.39
(t, 1H, J=9.5 Hz, 17-H), 5.35 (d, 1H, J=2.5 Hz, 6-H), 5.45 (s, 2H, 4′-
CH2-), 7.21 and 7.92 (d, 2H, J=8.0 Hz, 3″-H and 5″-H and d, 2H,
J=8.0 Hz, 2″- and 6″-H), 7.67 (s, 1H, 5′-H). 13C NMR (δ, ppm, CDCl3):
12.0 (C-18), 19.4 (C-19), 20.6, 21.6 (4″eCH3), 23.4, 25.9, 31.4, 31.5,
32.0, 36.5, 36.8, 37.2, 42.2, 44.2, 50.0, 53.1, 58.0 (4′-CH2-), 70.6 (C-
17), 71.6 (C-3), 121.0 (C-6), 123.4 (C-5′), 127.1 (C-1″), 129.0 and 129.7
(4C, C-2″, C-3″, C-5″ and C-6″), 140.1 (C-5′), 141.2 (C-4′), 143.8 (C-1″),
166.5 (C]O).
2.10.12. 17β-[4′-(4″-Nitrobenzoyloxymethyl)-1′H-1′,2′,3′-triazol-1′-yl]
androst-5-en-3β-ol (9k)
Compound 5b (315mg, 1mmol) and propargyl 4-nitrobenzoate
(7k, 411mg) were used for the synthesis as described in Section 2.8.
The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (10:90 v/v) to yield 9k (375mg, 72%) as a pale yellow
solid. Mp: 198–199 °C; Rf = 0.42 (ss B); [α]D20=−43 (c 1 in CHCl3).
(Found C, 66.82; H, 7.12; N, 10.64. C29H36N4O5 requires C, 66.90; H,
6.97; N, 10.76%). 1H NMR (δ, ppm, CDCl3): 0.56 and 0.99 (s, 3H, 18-H3
and s, 3H, 19-H3), 3.52 (m, 1H, 3-H), 4.41 (t, 1H, J= 9.5 Hz, 17-H),
5.35 (d, 1H, J= 5.0 Hz, 6-H), 5.51 (s, 2H, 4′-H2), 7.71 (s, 1H, 5′-H),
8.20 (d, 2H, J= 9.0 Hz, 3″-H and 5″-H), 8.26 (d, 2H, J= 9.0 Hz, 2″-H
and 6″-H). 13C NMR (δ, ppm, CDCl3): 12.0 (C-18), 19.4 (C-18), 20.6,
23.4, 25.9, 29.6, 31.4, 31.5, 32.0 (C-8), 36.8, 37.2, 42.2, 44.3 (C-13),
50.0 (C-9), 53.1 (C-14), 58.8 (4′-CH2-), 70.7 (C-17), 71.5 (C-3), 120.9
(C-6), 123.5 (C-2″ and C-6″), 123.7 (C-5′), 130.9 (C-3″ and C-5″), 135.2
(C-1″), 141.0 (C-5), 141.2 (C-4′), 150.6 (C-4″), 164.6 (C]O).
2.10.13. 17β-(4′-Hydroxymethyl-1′H-1′,2′,3′ -triazol-1′-yl)androst-5-en-
3β-ol (9l)
Compound 9 k (520mg, 1mmol) was dissolved in methanol (10ml)
containing NaOCH3 (27mg, 0.5mmol), and the solution was allowed to
stand for 24 h. It was then diluted with water, and the precipitate se-
parating out was ﬁltered oﬀ, and recrystallized from a mixture of ethyl
acetate/hexane to aﬀord 9l (320mg, 86%) as a white crystalline pro-
duct. Mp: 244–245 °C; Rf = 0.18 (ss B); [α]D20=−18 (c 1 in ethanol).
(Found C, 70.98; H, 9.11; N, 11.46. C22H33N3O2 requires C, 71.12; H,
8.95; N, 11.31%). 1H NMR (δ, pp, DMSO): 0.47 and 0.94 (s, 3H, 18-H3
and s, 3H, 19-H3), 4.51 (s, 2H, 4′-CH2-), 4.61 (s, 1H, 3-H), 5.14 (s, 1H,
17-H), 5.29 (s, 1H, 6H), 7.98 (s, 1H, 5′-H). 13C NMR (δ, ppm, DMSO):
11.7 (C-18), 19.1 (C-19), 20.1, 23.0, 25.1, 30.9, 31.3, 31.5 (C-8), 36.1,
36.2, 36.9, 42.1, 43.5, 49.6 (C-9), 52.2 (C-14), 55.0 (4′-CH2-), 69.3 (C-
17), 69.9 (C-3), 120.1 (C-6), 122.1 (C-5′), 141.3 (C-4′), 147.1 (C-5).
2.10.14. 17β-[4′-(4″-Nitrobenzoyloxymethyl)-5′-iodo-1′H-1′,2′,3′-
triazol-1′-yl]androst-5-en-3β-ol (9m)
Compound 5b (315.45 mg, 1mmol) and propargyl 4-nitrobenzoate
(7k, 204mg) were used for the synthesis as described in Section 2.9.
The crude product was chromatographed on silica gel with ethyl
acetate/CH2Cl2 (5:95 v/v) to yield 9m (375mg, 72%) as a white solid.
Mp: 198–200 °C; Rf = 0.55 (ss B); [α]D20=+89 (c 1 in CHCl3). (Found
C, 53.62; H, 5.68; N, 8.72. C29H35IN4O5 requires C, 53.87; H, 5.46; N,
8.67%). 1H NMR (δ, ppm, CDCl3): 0.77 and 1.01 (s, 3H, 18-H3 and 19-
H3), 3.53 (m, 1H, 3-H), 4.49 (t, 1H, J=8.5 Hz, 17-H), 5.38 (d, 1H,
J=5.0 Hz, 6-H), 5.49 (dd, 1H, J=20.0 Hz, J=13.0 Hz, 4′-CH2-), 8.24
(t, 2H, J=7.0 Hz, 3″-H and 5″-H), 8.28 (t, 2H, J=7.0 Hz, 2″- and 6″-
H). 13C NMR (δ, ppm, CDCl3): 14.1 (C-18), 19.4 (C-19), 20.8, 22.7,
23.6, 27.1, 29.4 (C-8), 31.5, 31.6, 31.9 , 32.0, 36.6 (C-9), 37.2, 38.2,
42.2, 45.6, (C-13), 50.0 (C-14), 53.7 (C-17), 59.1 (4′-CH2-), 71.6 (C-3),
121.1 (C-6), 123.5 (C-2″ and C-6″), 131.0 (C-3″ and C-5″), 135.1 (C-1′),
140.9 (C-5), 164.4 (C]O).
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2.10.15. 17β-(4′-Cyclopropyl-5′-iodo-1′H-1′,2′,3′-triazol-1′-yl)androst-5-
en-3β-ol (9n)
Compound 5 (315.45 mg, 1mmol) and cyclopropylacetylene (7d,
0.22 ml) were used for the synthesis as described in Section 2.9. The
crude product was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (5:95 v/v) to yield 9n (260mg, 53%) as a white crystalline
material. Mp: 210–213 °C; Rf = 0.52 (ss B); [α]D20=+63 (c 1 in
CHCl3). (Found C, 56.63; H, 6.91; N, 8.42. C24H34IN3O requires C, 6.80;
H, 6.75, N, 8.28%). 1H NMR (δ, ppm, CDCl3): 0.70 and 0.98 (s, 3H, 18-
H3 and s, 3H, 19-H3), 3.51 (m, 1H, 3-H), 4.40 (t, 1H, J=9.5 Hz, 17-H),
5.34 (d, 1H, J=4.5 Hz, 6-H). 13C NMR (δ, ppm, CDCl3): 7.24, 7.26,
7.63 7.63, 12.7 (C-18), 19.4 (C-19), 20.8, 23.5, 26.9, 29.7, 31.5, 32.0
(C-9), 37.2, 38.2, 42.2, 45.4 (C-13), 50.0 (C-14), 53.7 (C-1″), 70.0 (C-
17), 71.6 (C-3), 114.0 (C-5′), 121.1 (C-6), 140.9 (C-4′), 151.7 (C-5).
2.10.16. 17β-(4′-Cyclopropyl-5′-hydroxy-1′H-1′2′,3′-triazol-1′-yl)
androst-5-en-3β-ol (9o)
Compound 9n (127mg, 0.25mmol) were used for the synthesis
described in Section 2.10. 9r (76mg, 76%). Mp: 178–180 °C; Rf = 0.12
(ss B); [α]D20=−31 (c 1 in ethanol). (Found C, 72.67; H, 8.55, N,
10.68. C24H35N3O2 requires C, 72.51; H, 8.87; N, 10.57%).1H NMR (δ,
ppm, DMSO): 0.56 and 0.97 (s, 3H, 18-H3 and s, 3H, 19-H3), 1.98 (s,
4H, 2″-H and 3″-H), 2.62 (dd, 1H, J=21.5 Hz, J=10.5 Hz, 3-H), 4.18
(t, 1H, J=9.5 Hz, 17-H), 4.45 (m, 1H, 6-H), 5.37 (s, 1H, 5′-OH). 13C
NMR (δ, ppm, DMSO): 5.0 (C-18), 6.1 and 6.5 (C-2″ and C-3″), 12.2 (C-
19), 18.9 (C-8), 20.1, 23.0, 24.3, 27.2, 30.9, 31.4 (C-9), 31.6, 36.4,
36.7, 37.6, 43.8, 49.3 (C-14), 52.4 (C-1″), 61.5 (C-5′), 64.7 (C-17), 73.0
(C-3), 121.8 (C-6), 139.5 (C-4′), 169.6 (C-5).
2.11. Determination of the C17,20-lyase inhibition
The inhibitory eﬀect on the rat testicular C17,20-lyase enzyme ex-
erted by the new compounds were determined via an in vitro radio-
substrate incubation method [20]. In brief, adult Wistar rat testicular
tissue was homogenized with an Ultra-Turrax in 0.1 M HEPES buﬀer
(pH=7.3) containing 1mM EDTA and 1mM dithiotreitol. Aliquots of
this homogenate were incubated in 200 μl ﬁnal volume at 37 °C for
20min in the presence of 0.1 mM NADPH. 1 μM [3H]-17-hydro-
xyprogesterone was added to the incubate in 20 μl of a 25% (v/v)
propylene glycol solution. Test compounds were applied at 50 μM and
introduced in 10 μl of DMSO. (Such minor quantities of organic solvents
used here did not reduce the enzyme activity substantially). Control
incubates without test substances, and incubates with the reference
compound ketoconazole and abirateron were also prepared in every
series. Following
incubation, the androst-4-ene-3,17-dione formed and the 17-hy-
droxyprogesterone remaining were isolated through extraction and
TLC. C17,20-lyase activity was calculated from the radioactivity of the
androst-4-ene-3,17-dione obtained. Two experiments were performed
with each test compound and the standard deviations of the mean en-
zyme activity results (S.D.) were within ± 15%. IC50 values were de-
termined for the more active inhibitors. In this case, the conversion was
measured at 5 or 6 diﬀerent concentrations of the test compound. IC50
results were calculated using an un-weighted iterative least squares
method for four-parameter logistic curve ﬁtting. IC50 of unlabelled 17-
hydroyprogesterone substrate, as well as abiraterone, and another
clinically relevant, nonsteroidal imidazole P45017α inhibitor, ketoco-
nazole were measured as reference. Reference IC50 values were de-
termined for unlabelled 17-hydroxyprogesterone substrate (1.6 μM) as
well as for abiraterone (0.0125 μM) and ketoconazole (0.32 μM).
2.11.1. Time dependence of inhibitory eﬀect
Time-dependent change in the inhibitory eﬀect was investigated by
preincubation with the testicular homogenate. Testicular homogenate
in incubation mixture was preincubated with IC50 concentration in the
presence or the absence of NADPH cofactor for 40min at 37 °C, then the
inhibition test was started by the addition of the substrate.
Scheme 1. Reagents and conditions: (i) TsCl, pyridine, rt, 24 h; (ii) NaN3, DMF, 100 °C, 24 h; (iii) Ph3P, imidazole, I2, toluene, 80 °C, 2 h; (iv) NaN3, DMF, 60 °C, 24 h.
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Scheme 2. Reagents and conditions: Ph3P or Et3N, CuI, CH2Cl2, rt, 24 h.
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2.11.2. Investigation of binding mechanism
Reversibility of test compounds was investigated via preincubation
and charcoal adsorption method. Testicular homogenate in incubation
mixture was preincubated with high concentration (10 μM and 50 μM)
of the tested compounds, in the presence of NADPH cofactor for 10 and
40min at 37 °C. After the addition of charcoal suspension in 0.6% ﬁnal
concentration, the preincubated samples were kept on ice for 15min
and centrifuged at 4 °C. Supernatants were drained and used for in-
hibition tests.
3. Results and discussion
3.1. Synthetic studies
To prepare novel steroid triazoles via 1,3-dipolar cycloaddition,
17α- and 17β-azidoandrost-5-en-3β-ol (3b and 5b) were selected as
starting compounds. The synthetic strategy for the preparation of the
starting azides is illustrated in Scheme 1 and the synthesis of steroidal
1,2,3-triazoles by CuAAC is outlined in Scheme 1 and 2.
3β-Acetoxy-androst-5-en-17β-ol (1) was esteriﬁed with p-toluene-
sulfonyl chloride to give tosylate 2, which then underwent facile SN2
substitution with NaN3 in N,N-dimethylformamide to furnish the cor-
responding 17α-azido compound 3a. Deacetylation of 3a by the
Zemplén method produced 17α-azido-androst-5-en-3β-ol 3b.
Iodination of 1 by the Appel reaction proceeded with Walden inversion
to yield 3-acetoxy-androst-5-en-17α-iodide 4 [7]. Further nucleophilic
exchange reaction with NaN3 in N,N-dimethylformamide furnished
17β-azido compound 5a in moderate yield. The exchange reaction was
accompanied by elimination to give 3-acetoxy-androst-5,16-diene (6)
too.
The 17-azido derivatives (3b or 5b) were subjected to azide–alkyne
CuAAC reactions with substituted phenylacetylenes (7a–c), small cy-
cloalkyl acetylenes (7d–f), 2-piridylacetylene (7g), phenyl propargyl
ether (7h), and propargyl phenyl esters (7i-k). The CuAAC of 3b or 5b
with substituted acetylenes (7a–k) were carried out in reﬂuxing CH2Cl2
with CuI as catalyst in the presence of Et3N (0.2 equivalent) to obtain
the required 1,4-disubstituted triazoles (8a–k and 9a–k) in moderate
yields after 24 h.
Alkaline hydrolysis of 4′-benzoyloxymethyl triazoles 8i–k and 9i–k
yielded polar 4′-hydroxymethyltriazolyl derivatives 8l and 9l.
We found earlier that the CuAAC reaction in the presence of Et3N is
accompanied by building of 5′-iodo-1,4-triazoles in small quantities
[21]. When 1.5 equivalent of ICl was used as electrophile in the pre-
sence of 10 equivalents of CuI and Et3N, the quantity of 5′-iodo-tria-
zoles increased to 49–72%. With this method we prepared 4′-p-ni-
trobenzoyloxymethyl-5′-iodo- and 4′-cyclopropyl-5′-iodo triazoles
8m–n and 9m–n. Acetolysis of 8n and 9n in acetic anhydride in the
presence of KOAc followed by alkaline hydrolysis yielded 4′-cyclo-
propyl-5′ hydroxy triazolyl derivatives 8o and 9o.
3.2. C17,20-lyase inhibition studies
The P45017α catalyzed biotransformation of C21 steroids consists of
hydroxylation and a subsequent side-chain cleavage at the C-17 carbon.
This second C17,20-lyase process is the rate-limiting step in the synthesis
of the C19 preandrogens. Inhibition of the C17,20-lyase activity is,
therefore, the primary evaluation criteria of compounds with presumed
androgen-withdrawing eﬀect achieved by blockade of the P45017α
[1,5,22]. In this study we investigated inhibition against C17,20-lyase
activity of P45017α exerted by the new androst-5-en-3β-ol derivatives
possessing diverse C-substituted triazolyl substituents or the azide
group in 17α or 17β position.
3.2.1. Inhibition eﬀect of the17-heterocyclic compounds
Several related 5-membered N-containing imidazole, pyrazole,
triazole, and tetrazole isomers of androstane compounds were studied
as potential C17,20-lyase inhibitors [5,6,23–25]. We have previously
observed with C-17β and C-17β phenyl-substituted pyrazolinylan-
drostenes that the extended 17β heterocyclic side-chain with various
substituted aromatic rings may have substantial inhibitory eﬀect [11].
Structural investigations proposed the existence of a second hydro-
phobic binding pocket beside the heme structure, which also supports
the inhibitor development strategy involving an adjacent phenyl group
on the C-17 substituent [26]. As a further example, related studies with
galeterone also indicate that compounds with more spacious aromatic
side chains may improve aﬃnity and inhibitory eﬀect towards P45017α,
Table 1
In vitro inhibition of rat testicular C17,20-lyase by test compounds 8a–o and 9a–o.
No. 8, 9 IC50 Relative conversion % 50 μM Relative conversion % 10 μM IC50 Relative conversion % 50 μM Relative conversion % 10 μM
a 88 ± 4 92 ± 3 95 ± 5 95 ± 7
b 89 ± 6 89 ± 1 107 ± 10 100 ± 8
c 81 ± 3 97 ± 5 87 ± 4 92 ± 5
d 21.6 ± 7.5 40 ± 7 83 ± 5 76 ± 7 74 ± 3
e 70 ± 8 82 ± 3 91 ± 8 90 ± 10
f 89 ± 11 85 ± 8 80 ± 6 92 ± 2
g 58 ± 3 77 ± 7 74 ± 7 90 ± 5
h 61 ± 7 62 ± 4 86 ± 8 86 ± 5
i 3.5 ± 0.8 5 ± 1 32 ± 5 79 ± 5 82 ± 6
j 71 ± 7 86 ± 12 94 ± 11 90 ± 4
k 9.2 ± 3.4 5 ± 2 31 ± 4 88 ± 8 100 ± 10
l 33 ± 23 49 ± 2 63 ± 3 74 ± 7 90 ± 5
m 72 ± 8 84 ± 7 75 ± 3 85 ± 7
n 98 ± 10 86 ± 7 72 ± 4 93 ± 9
o 3.1 ± 1.4 15 ± 2 26 ± 5 94 ± 7 98 ± 5
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and the extension of the side chain may be useful in modiﬁcation of the
activity proﬁle of a pharmacon candidate [27,28].
In this report we investigated inhibition against C17,20-lyase activity
of P45017α exerted by the new androst-5-en-3β-ol derivatives (8 and 9)
possessing diverse C-substituted triazolyl substituents in the 17α and
17β position (Tables 1 and 2).
Compounds bearing 17β-triazolyl substituents on the androst-5-en-
3β-hydroxy skeleton (9) exerted weak inhibition with the relative
conversions more than 70% even in the relatively high 50 μM test
concentration (Table 1). In the 17α-triazolyl series two cyclopropyl
derivatives (8d, 8o) and three phenyl ester derivatives (8i, 8k, 8l) ex-
erted more pronounced inhibition (Table 1). Compounds 8o and 8i
were found to be the best inhibitors among them with IC50 values
3.1 μM and 3.5 μM, respectively (Table 1, Fig. 1). Compounds 8g in the
17α-triazolyl series and 9g in the 17β series containing heteroaryl
substituents at the C-4′ carbon were also weak inhibitors. In the series
of the cycloalkyl-substituted 17α-triazolyl compounds (8d–f) a de-
creasing inhibition could be observed with increasing carbon numbers
in the cycle. An additional iodo substituent on the triazole ring (8-m,n,
9m,n) was disadvantageous for inhibition, whereas a hydroxyl group at
the same position (8o) improved the eﬀect.
These results demonstrate substantial inhibitory eﬀect of the C-4′-
hydroxymethyl benzoate 8i and p-nitrobenzoate 8k to the enzyme.
Their IC50 values indicate aﬃnities to the enzyme similar to that of the
substrate. The presence as well as the ﬂexible and appropriate posi-
tioning of phenyl group seems to be essential for the good binding such
as the precursor alcohol 8l. The C-4′ coupled phenyl group (8a), and the
C4′-phenoxymethyl ether (8h) derivatives were weak inhibitors. The p-
nitro function on the phenyl group (8k) decreased the inhibition in a
lesser, whereas the p-methyl group (8j) decreased in a higher extent.
Table 2
In vitro inhibition of rat testicular C17,20-lyase by test compounds 3b and 5b.
No. IC50 Relative conversion % 50 μM Relative conversion % 10 μM
3b 21.1 ± 6.8 42 ± 4 64 ± 9
5b 0.60 ± 0.18 17 ± 3 15 ± 2
Fig. 1. Concentration-dependent inhibitory eﬀects of test compounds 5b, 8o and 8i on the in vitro activity of C17,20-lyase. [I]: inhibitor concentration in μM.
Fig. 2. Inhibitory potential of the IC50 concentration of 5b and reference
compounds (abiraterone and ketoconazole) with or without 40min pre-
incubations with the rat testicular homogenate. Following the preincubation
period, the usual incubation procedure was applied.
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Our results reveal that stereoisomerism at the C-17 of the new androst-
5-en-3β-ol derivatives inﬂuences the C17,20-lyase eﬀect. Inhibitors were
found only in the 17α-triazolyl series, whereas the 17β counterparts (9)
were found to be almost inactive in the C17,20-lyase test.
3.2.2. Inhibition eﬀect of the 17-azido compounds
Only a few steroid azides similar to those investigated here can be
found in the literature. The synthesis and antituberculosis activity of
17α-azido-5α-androstan-3β-ol was investigated by Merlani et al. [29].
The neuroactive 17α- and 17β-azido-5β-androstan-3α-ols were studied
by Vidnra et al. [30]. 17-Azidomethyl-androst-5,16-dien-3β-ol was
synthesized by the group of Njar and Brodie during their P45017α in-
hibitor development studies [31]. P45017α or C17,20-lyase inhibitory
potential of these related compounds, however, was not reported in
either of the corresponding publications.
Wright et al. investigated the inhibition of 19-azido-4-androstene-
3,17-dione against the aromatase, another cytochrome P450 dependent
enzyme in the steroid hormone metabolism [32]. They have found re-
versible inhibitor binding and hypothesized that the ﬁrst nitrogen atom
in the azide group (attached directly to the C-19 carbon) is most likely
to be involved in coordination to the heme iron of aromatase.
Other, non-steroidal primary azides were found to be converted to
the corresponding aldehydes via biocatalysis of myoglobin, another
heme-dependent metalloprotein similar to cytochrome P450 [33]. The
proposed binding and reaction mechanisms of the myoglobin-catalyzed
azide reaction also indicate that the ﬁrst-nitrogen is coordinated to the
heme iron of the active center.
In this report we investigated C17,20-lyase inhibition of the two
androst-5-en-3β-ol compounds possessing azide group in the 17α or
17β position. Our results revealed that the 17-azido androstene com-
pounds (3b, 5b) tested here were able to inhibit the C17,20-lyase ac-
tivity. Stereoisomerism at the C-17 atom inﬂuenced the eﬀect in the
pair of the 3β-hydroxy-5-androstene compounds (3b, 5b). 17β-Azido
derivative 5b was found to be more eﬀective (IC50= 0.60 μM) than
17α-azide 3b (IC50= 21 μM) (Table 2, Fig. 1). The IC50 parameter of 5b
indicated a 2.5-fold stronger binding compared to the substrate, and its
inhibitory potential was found to be close to that of the nonsteroidal
imidazole reference ketoconazole.
Potent inhibition of the 17β-azido 5b is an interesting ﬁnding;
therefore, we further investigated inhibitory properties of this com-
pound.
3.2.2.1. Time dependence of inhibitory eﬀect of 5b. The possible time-
dependent change of inhibitory eﬀect of 5b was investigated in
experiments in which the compound was applied in its IC50
concentration (0.60 μM) and preincubated with the testicular
homogenate before the usual inhibition test. No diﬀerence was found
between the normal and the preincubated samples either in case of test
compound 5b or the reference abiraterone and ketoconazole (Fig. 2).
The presence of cofactor during the preincubation had no inﬂuence
either on the measured inhibitory potentials. This observation indicates
that conversion of the tested compound, which could modify the
inhibitory potential of 17β-azido-androst-5-en-3β-ol 5b, does not
occur under the conditions of incubation procedures applied.
3.2.2.2. Reversibility of inhibition of 5b. Reversibility of the inhibition
Fig. 3. Investigation of inhibition reversibility of 5b and reference compounds (abiraterone and ketoconazole). Compounds were preincubated with rat testicular
homogenate. Following a charcoal separation step, the usual incubation procedure was applied.
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was studied via preincubation with high concentration of the test
compounds followed by the removal of unbound and reversibly
bound inhibitor molecules by charcoal adsorption. Samples pretreated
with the known reversible inhibitor compound ketoconazole as
reference [34] displayed almost non-inhibited C17,20-lyase activity
[34], whereas irreversible reference inhibitor compound abiraterone
[7] blocked enzyme activity (Fig. 3). Incubations pretreated with
compound 5b resulted in conversions close to those in the inhibited
control inhibition tests with high inhibitor concentration. These results
indicate that 5b molecules cannot be removed by charcoal treatment
from the binding, that is binding to the enzyme takes place via an
irreversible mechanism. Note that in the case of abiraterone and several
other C-17 heterocyclic P45017α inhibitors, the Δ16,17 double bond not
only increases the inhibitory potency but also switches the binding
mode from reversible to irreversible [7]. Nevertheless, the irreversible
binding of 17β-azido-androst-5-en-3β-ol (5b) occurs in the absence of
Δ16,17 double bond.
3.2.2.3. Aromatase inhibitory eﬀect of 5b. Taking into account of the
aromatase inhibitory eﬀect of 19-azido-4-androstene-3,17-dione [32]
and certain P45017α inhibitor abiraterone analogs [35], we performed
tests whether 5b is capable of inhibiting this enzyme. The in vitro
radiosubstrate incubations were based on similar incubation
methodology as described here for the C17,20-lyase. Incubations with
high concentrations (10 µM and 50 µM) resulted in relative conversions
similar to the non-inhibited controls (results are not shown). These
results indicate that 17β-azido-androst-5-en-3β-ol 5b does not inhibit
aromatase activity substantially.
4. Summary
P45017α is a pivotal enzyme of steroid biosynthesis. Inhibition of its
C17,20-lyase activity leads to suppressed androgen production, which
can be applied for antiandrogen therapies. Results on C17,20-lyase in-
hibitory eﬀect of our new aryl-substituted 17-triazolyl androstenes re-
vealed that compounds bearing a 17α-heterocyclic side chain may also
have substantial aﬃnity to this enzyme. Our results veriﬁed that ex-
tension of the C-17 side chain may improve inhibitory potential. In
addition, an azido group on the steroidal C-17 atom is a suitable
pharmacophore in the inhibition of the C17,20-lyase activity. The potent
inhibition of the azido compound is an interesting ﬁnding worth further
investigations.
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